TP53 and adenoma: Compared with the CIN pathway, the adenoma–carcinoma pathway, in which MSI is involved, APC and TP53 are mutated less frequently in MSI, whereas mutations in tumor suppressor genes, such as transforming growth factor beta receptor 2, are observed in more than 90% of MSI colorectal tumors [18].